Phase I dose-escalation trial of mepacrine in patients with liver metastases or advanced liver cancer.

Trial Profile

Phase I dose-escalation trial of mepacrine in patients with liver metastases or advanced liver cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2014

At a glance

  • Drugs Mepacrine (Primary)
  • Indications Liver cancer; Liver metastases
  • Focus Adverse reactions
  • Sponsors Cleveland BioLabs
  • Most Recent Events

    • 16 Apr 2014 Results published in a Cleveland BioLabs media release.
    • 16 Apr 2014 Primary endpoint 'Maximum-tolerated-dose' has been met.
    • 16 Apr 2014 Status changed from recruiting to completed, according to a Cleveland BioLabs media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top